Risk Prediction for Development of Adverse Effects FOllowing Radiotherapy for Prostate Cancer

 描述(由申请人提供)：我的研究和职业重点是预测癌症治疗的反应，特别关注负面影响生活质量的不良影响。我接受过癌症生物学和遗传流行病学方面的培训，我的长期职业目标是建立一个由NCI支持的独立研究计划，专注于预测癌症治疗结果的基因测试的开发和临床实施。我的短期研究兴趣主要集中在放射治疗反应的遗传预测因素上。这一研究领域被称为“放射基因组学”，是一个令人兴奋的相对较新的领域。这项工作的最终目标是开发一种临床上有用的基因测试。 这可以根据癌症患者出现不良放射治疗效果的风险对他们进行分层。是这样的 测试可以用来向接受癌症诊断的个人提供信息，帮助他们和他们的医生一起选择最好的疗程，将不良反应降至最低。这项工作有可能显著提高数百万癌症幸存者的生活质量。在这个K07奖项的背景下，我的直接目标是开发和测试基于遗传和非遗传风险因素的综合风险模型，以发展用于前列腺癌治疗的放射治疗的尿路、直肠和性不良反应。拟议的研究旨在1)利用NCI支持的放射基因组学联盟的宝贵资源，利用现有的大量放射基因组数据集来开发风险模型；以及2)在罗切斯特大学威尔莫特癌症研究所进行的一项独立的前瞻性研究中测试这些风险模型。预计拟议的研究将产生重要成果，并提供为我开始独立职业生涯做准备所需的额外经验和培训。我的研究活动将得到导师指导、教学课程以及参加研讨会和全国会议的补充。我组建了一个杰出的导师团队，由临床癌症研究、放射生物学和肿瘤学以及前列腺癌领域的领导者组成。罗切斯特大学医学中心和威尔莫特癌症研究所提供了一个出色的环境，让他们完成这项重要的工作，并培训成为临床转化性癌症研究的领先者。

 DESCRIPTION (provided by applicant): My research and career focus is on predicting response to cancer treatment, with a specific concentration on adverse effects that negatively impact quality of life. I have been trained in cancer biology and genetic epidemiology, and my long-term career goal is to establish an NCI-supported independent research program focused on development and clinical implementation of genetic tests that predict for cancer treatment outcomes. My short-term research interests focus specifically on genetic predictors of response to radiation treatment. This area of research, termed 'radiogenomics', is an exciting, and relatively new field. The ultimate goal of this work is to develop a clinically useful genetic test that can stratify cancer patients as to their risk of developing adverse radiotherapy effects. Such a test could be used to provide information to individuals receiving a cancer diagnosis that will help them, along with their physician, choose the best course of treatment that will minimize adverse effects. This work has potential to significantly improve quality-of-life for millions of cancer survivors. My immediate goal within the context of this K07 award is to develop and test integrative risk models, based on genetic and non-genetic risk factors, for development of urinary, rectal and sexual adverse effects of radiotherapy used in treatment of prostate cancer. The proposed research aims to 1) develop risk models using the a large set of existing radiogenomics datasets, leveraging valuable resources of the NCI-supported Radiogenomics Consortium; and 2) test these risk models in an independent, prospective study conducted at the University of Rochester Wilmot Cancer Institute. The proposed study is expected to yield important results as well as provide additional experience and training needed to prepare me to embark on an independent career. My research activities will be complemented by mentorship, didactic coursework and attendance of workshops and national meetings. I have assembled an outstanding mentor team comprised of leaders in clinical cancer research, radiation biology and oncology, and prostate cancer. The University of Rochester Medical Center and Wilmot Cancer Institute provide an outstanding environment in which to perform this important work and train to become a leader in clinical translational cancer research.